Results 41 to 50 of about 1,126,910 (189)

Cardiovascular risk and inhibition of cyclooxygenase: traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors

Italian Journal of Medicine, 2013
BACKGROUND The development of non-selective nonsteroidal anti-inflammatory drugs (tNSAIDs) and, more recently, of selective inhibitors of the cycloooxygenase-2 isoform (COXIBs), has contributed greatly towards the effective management of patients with ...
M. Campanini, G. Mathieu
doaj   +1 more source

Three-Dimensional Quantitative Structural Activity Relationship (3D-QSAR) Studies of Some 1,5-Diarylpyrazoles: Analogue Based Design of Selective Cyclooxygenase-2 Inhibitors

Molecules, 2000
Selective cyclooxygenase inhibitors have attracted much attention in recent times in the design of new non-steroidal anti-inflammatory drugs (NSAID).
Hosahalli S. Subramanya, Jagarlapudi A. R. P. Sarma, Dayam Raveendra, Ram K. R. Jetti, Bulusu Gopalakrishnan, Gautam R. Desiraju   +5 more
doaj   +1 more source

m-Terphenylamines, Acting as Selective COX-1 Inhibitors, Block Microglia Inflammatory Response and Exert Neuroprotective Activity

Molecules, 2023
Inhibition of cyclooxygenase-2 (COX-2) has been extensively studied as an approach to reduce proinflammatory markers in acute brain diseases, but the anti-neuroinflammatory role of cyclooxygenase-1 (COX-1) inhibition has been rather neglected.
Damiano Rocchi, Juan F. González, Olmo Martín-Cámara, Maria Grazia Perrone, Morena Miciaccia, Antonio Scilimati, Celine Decouty-Pérez, Esther Parada, Javier Egea, J. Carlos Menéndez   +9 more
doaj   +1 more source

VIRTUAL SCREENING CAMPAIGNS ON ISOFLAVONES TO DISCOVER POTENT CYCLOOXYGENASE-2 INHIBITORS

Jurnal Farmasi Sains dan Komunitas, 2017
By employing recently published structure-based virtual screening (SBVS) to identify potent cyclooxygenase-2 (COX-2) inhibitors, all isoflavones collected by ZINC15 database were virtually screened. There were 3371 isoflavones in ZINC15 database and 1356
Enade Perdana Istyastono
doaj   +1 more source

Hypertension and Cyclooxygenase-2 Inhibitors [PDF]

Hypertension, 2004
Cyclooxygenase (COX)-inhibiting NSAIDs are widely prescribed to treat arthritis, exerting analgesic and antiinflammatory effects via their capacity to block endogenous prostaglandin synthesis.1,2 Unfortunately, their widespread use has been associated with an increased risk of developing hypertension,3,4 and clinical experience with COX-2 selective ...
Chuan-Ming Hao, Matthew D. Breyer
openaire   +1 more source

Cyclooxygenase-2 Inhibitors in Gynecologic Practice [PDF]

Clinical Medicine & Research, 2003
Treatment of pain and inflammation associated with dysmenorrhea, endometriosis, ovarian cancers and operative procedures is an ongoing challenge in gynecology. Understanding the roles of prostanoids and estrogen in these conditions and appropriate treatment approaches have advanced beyond traditional nonsteroidal anti-inflammatory drugs.
openaire   +2 more sources

Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line

Journal of Pharmacopuncture, 2017
Objectives: Study of the mechanisms involved in cancer progression suggests that cyclooxygenase enzymes play an important role in the induction of inflammation, tumor formation, and metastasis of cancer cells.
Pouran Makhdoumi, Afshin Zarghi, Bahram Daraei, Gholamreza Karimi   +3 more
doaj   +1 more source

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: POSSIBILITIES OF REDUCING BACK PAIN INTENSITY IN PATIENTS WITHOSTEOPOROSIS

Современная ревматология, 2009
Objective: to evaluate the efficiency and tolerability of a 10-day course of therapy with different doses of meloxicam in patients with osteoporosis and back pain. Subjects and methods.
N V Toroptsova, T A Korotkova, O A Nikitinskaya   +2 more
doaj   +1 more source

Screening of ferulic acid related compounds as inhibitors of xanthine oxidase and cyclooxygenase-2 with anti-inflammatory activity

, 2016
The ferulic and gallic acid related compounds from natural origin were studied against xanthine oxidase and cyclooxygenase-2 along with their anti-inflammatory activity.
S. Nile, E. Ko, D. Kim, Y. Keum
semanticscholar   +1 more source

Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.

PLoS ONE, 2016
BackgroundEvidence on the benefits of combining cyclooxygenase-2 inhibitor (COX-2) in treating non-small cell lung cancer (NSCLC) is still controversial.
Yuan Yuan Zhou, Zhi Gang Hu, Fan Jun Zeng, Jiao Han   +3 more
doaj   +1 more source